Table 1. Clinical information of the study participants.
| Participant | Gender | Age at infection | Risk exposurea | HCV genotype | HCV RNA range (log10 IU/ml)b | Early specimen | Late specimen | ||||||||
| Years infected | KnodellFibrosis stage | AST (U/L)c | ALT (U/L)c | AFP (ng/ml)c | Years infected | KnodellFibrosis stage | AST (U/L)c | ALT (U/L)c | AFP (ng/ml)c | ||||||
| 1 | M | 16 | IDU | 1a | 4.7–7.3 | 26 | 4 | 176 | 258 | 8.9 | 38 | 4 | 47 | 72 | 5.2 |
| 2 | F | 44 | IDU | 1a | 5.8–6.7 | 3 | 1 | 50 | 62 | 1.5 | 14 | 1 | 38 | 43 | 3.7 |
| 3 | F | 30 | Others | 1a | 4.7–6.2 | 15 | 1 | 57 | 71 | 9.0 | 25 | 3 | 32 | 30 | 14.0 |
| 4 | F | 29 | Others | 1a | 5.7–6.3 | 7 | 0 | 52 | 49 | 2.0 | 13 | 0–1 | 43 | 38 | 3.2 |
| 5 | M | 25 | IDU | 1a | 6.0–7.3 | 29 | N/A | 25 | 32 | 2.9 | 35 | N/A | 24 | 33 | 3.7 |
| 6 | M | 25 | IDU | 1a | 6.1–7.0 | 13 | 1 | 55 | 126 | 3.8 | 20 | N/A | 30 | 67 | 5.7 |
| 7 | F | 27 | IDU | 1a | 6.4–7.2 | 2 | N/A | N/A | N/A | N/A | 23 | 3 | 66 | 81 | 3.4 |
| 8 | F | 15 | BT, IDU | 1b | 5.6–6.3 | 32 | 1 | 68 | 32 | 3.0 | 37 | 1 | 44 | 35 | 3.6 |
| 9 | F | 32 | Others | 1a | 5.7–6.8 | 10 | 1 | 38 | 74 | 1.7 | 15 | 1 | 41 | 63 | 1.7 |
a
IDU, intravenous drug use; BT, blood transfusion; others include tattooing, body piercing, sharing personal care items, blood-to-blood contact during sexual activity, intranasal cocaine use, and unknown.
b
HCV RNA range (log10 IU/ml) was estimated as the range of all documented RNA titers of the archived specimens until the late time point for each participant.
c
AST, ALT and AFP levels were estimated as the mean of all documented enzymatic levels of the year of the early or late time points for each participant.